What You Should Know:
- Abbott, a provider of continuous glucose monitoring (CGM) biowearable technology, has announced a landmark agreement with Epic Systems, a major provider of electronic health records (EHR).
- The first-of-its-kind collaboration for Abbott will integrate patient glucose data from its leading FreeStyle Libre CGM systems directly into Epic's EHR platform across the United States.
FreeStyle Libre Integration with Epic Aura
The integration leverages
Read More
Abbott
Glooko Integrates Abbott FreeStyle Libre CGM, Enhancing Diabetes Management
What You Should Know:
- Glooko, a provider of integrated digital health solutions for diabetes management, has announced a significant expansion of its platform's capabilities with the integration of Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) systems in the United States.
- The newly implemented integration allows individuals with diabetes to seamlessly synchronize data from their FreeStyle Libre CGM systems with other vital health metrics, including insulin
Read More
Abbott Opens State-of-the-Art Diabetes Care Manufacturing Facility in Kilkenny, Ireland
What You Should Know:
- Abbott, a global healthcare leader, has officially opened its new global manufacturing center of excellence for Abbott’s diabetes care business in Kilkenny, Ireland.
- Abbott's FreeStyle Libre portfolio is the world's leading continuous glucose monitoring system, helping more than 6 million people with diabetes across over 60 countries.
Boosting Irish Economy and Manufacturing Capabilities
The Kilkenny facility is part of a €440 million
Read More
Abbott’s FreeStyle Libre CGM Systems Now Cleared for Use During Imaging Procedures
What You Should Know:
- Abbott announced that its FreeStyle Libre 2 and 3 continuous glucose monitoring (CGM) systems have received FDA clearance for use during common imaging procedures, including X-rays, CT scans, and MRIs.
- The development makes Abbott's systems the first and only patient-applied CGM sensors approved for use during these screenings, offering greater convenience and potential cost savings for people with diabetes.
Improving Diabetes
Read More
Abbott Launches OTC Continuous Glucose Monitor, Lingo
What You Should Know:
- Abbott, a global healthcare company, has announced the U.S. availability of Lingo, a continuous glucose monitoring (CGM) system designed for individuals who want to improve their overall health and wellness.
- Lingo is the first CGM available without a prescription designed for individuals who want to improve their overall health and wellness, regardless of whether they have diabetes.
A Powerful Tool for Health Management
Lingo combines a biosensor
Read More
Abbott and Medtronic Partner to Integrate CGM System & Insulin Delivery Devices
What You Should Know:
- Abbott and Medtronic announced a groundbreaking partnership to develop an integrated continuous glucose monitoring (CGM) system designed to seamlessly work with Medtronic’s automated insulin delivery (AID) and smart insulin pen systems.
- The strategic collaboration aims to improve diabetes management by enabling more precise insulin dosing and reducing the burden on patients.
CGM System and Insulin Delivery Devices Integration
The new CGM sensor,
Read More
Abbott Receives FDA Approval for World’s First Dual Chamber Leadless Pacemaker
What You Should Know:
The U.S. Food and Drug Administration (FDA) approves Abbott’s AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms.Abbott’s breakthrough technology enables the world's first beat-to-beat, wireless communication and synchronization between two leadless pacemakers, which are smaller than a AAA batteryLeadless pacemakers provide a new minimally invasive option
Read More
Key Challenges and Solutions to Enhance the Post-Procedure Experience
What You Should Know:
- Abbott today released the latest installment in the company’s multi-year Beyond Intervention series of global healthcare market research designed to uncover challenges that arise within the patient journey of people living with cardiovascular disease and to identify opportunities for patient care improvement.
- The latest report stems from a survey of more than 2,000 patients, physicians and healthcare leaders, and reveals
Read More
The Quickening Pulse of the Ambulatory Diagnostic Cardiology Market
The Global Ambulatory Diagnostic Cardiology Market is evolving at a rapid pace, driven by technological developments, and shifting models of healthcare service delivery and funding. The overall market will grow from $2.5 billion in 2021, to $3.3 billion by 2026, with Long-Term ECG and, to a lesser extent, Mobile Cardiac Telemetry (MCT), being the principal engines of growth. Unsurprisingly, these two markets are garnering serious attention from large incumbent vendors in the more established
Read More
Q/A: Podimetrics CEO Talks Preventing Diabetic Amputations
Diabetes prevention is one of the biggest challenges in the healthcare industry as more than 37 million Americans (11.3% of the population) suffer from this debilitating chronic disease. As we close the year out, we sat down with Jon Bloom, MD, CEO and Co-founder of diabetic healthcare tech company Podimetrics to learn how the industry and his company are working to implement health equity change to serve patients living with advanced diabetes. The company’s FDA-cleared SmartMat provides a
Read More
